AstraZeneca PLC (LSE:AZN) - Share price


Stock Report

AstraZeneca PLC AZN

Last Price
GBX6,013.00

Day Change
75.00|1.26%

As of 23/05/2019
18:45:02 BST | GBX
Minimum 15 Minutes Delay.

Last Close5,938.00p
Day Range5,982.00 - 6,064.00
Mkt Cap78.88Bil
52-Wk Range5,110.00 - 6,540.00
Yield %0.00
ISINGB0009895292
Volume2,917,097
P/E34,164.77
P/S3.45
P/CF29.10

Share Price

Total Returns 23/05/2019

 Chg (%)  
More ...
AstraZeneca PLC1.66 
FTSE 100 TR GBP-3.27
 
Financials
201620172018
More ...
Income Statement
Turnover23,002.0022,465.0022,090.00
Operating Profit3,572.002,052.001,510.00
Net Profit3,406.002,868.002,050.00
Reported EPS2.772.371.70
Balance Sheet
Current Assets13,262.0013,150.0014,609.00
Non Current Assets49,264.0050,204.0045,060.00
Total Assets62,526.0063,354.0060,651.00
Current Liabilities15,256.0016,383.0016,292.00
Total Liabilities---
Total Equity16,669.0016,642.0014,044.00
Cash Flow
Operating Cash Flow4,557.004,032.003,155.00
Net Change in Cash-1,148.00-1,686.001,537.00

Regulatory News

DateAuthor Headline
28/12/2018David Brenchley 5 Worst-Performing FTSE 100 Stocks in 2018
The FTSE 100 has suffered from numerous troubles in 2018 - hit by trade and political uncertainty. We round up the worst performers
27/12/2018David Brenchley 5 Best FTSE 100 Stocks of 2018
It has been a troubled year for UK stocks, with fewer than a third of the FTSE 100 constituents in the green. We round up the best performers
13/09/2018David Brenchley ETF Investors Look to Healthcare Stocks
The S&P 500’s Healthcare sector has returned 18% in the year-to-date, almost twice that of the wider index’s 9.5% - and ETF investors are getting in on the act
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
07/05/2019PurchaseMr. Marc Dunoyer5,800.008,500493,000.00
30/04/2019PurchasePhilip A J Broadley5,738.0052029,838.00
29/04/2019PurchaseMs. Sherilyn S. (Sheri) McCoy19.094,74490,559.00
29/04/2019PurchaseMs. Sherilyn S. (Sheri) McCoy19.092003,817.00

Company Profile

AstraZeneca PLC belongs to the healthcare sector. The company develops and markets pharmaceutical products for various therapeutic classes such as gastrointestinal, cardiovascular, respiratory, cancer, immunology, and neuroscience.

Sector

Drug Manufacturers - Major

Index

FTSE 100 ,FTSE 350 ,FTSE All Share ,FTSE Eurotop 100 ,FTSE Eurotop 300

Next Event 25/07/2019

Half-Yearly Results
Ratios
Comp
More ...
PER (E)38.97
Div Yld (E)3.76
PEG (E)2.08
ROCE6.29
Op Mrgn0.07
EPS Grwth-0.88
Dividends
PreviousLatest
More ...
Record Date10/08/1801/03/19
Ex-Div09/08/1828/02/19
Paid10/09/1827/03/19
Amnt68.40146.80
Directors
More ...
Non-Executive DirectorMs. Sherilyn S. (Sheri) McCoy
Non-Executive Director, ChairmanMr. Leif Johansson
Executive Director, Chief Financial OfficerMr. Marc Dunoyer
Non-Executive DirectorMr. Marcus Wallenberg
Executive Director, Chief Executive OfficerMr. Pascal Soriot
Non-Executive DirectorPhilip A J Broadley
Non-Executive DirectorMr. Graham Andrew Chipchase
Non-Executive DirectorProf Genevieve Berger
Non-Executive DirectorDeborah DiSanzo
Non-Executive DirectorProfessor Nazneen Rahman
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2019 Morningstar. All rights reserved.